Newsarchive till 2022

Published
2022/11/28

Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer’s Disease Conference (CTAD)

Published
2022/11/23

Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares

Published
2022/11/22

Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

Published
2022/11/14

Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022

Published
2022/09/30

Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress

Published
2022/09/30

Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million

Published
2022/09/26

Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022

Published
2022/07/31

Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022

Published
2022/07/31

Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique Opportunity in AD

Published
2022/06/23

Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD

Published
2022/06/22

Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022

Published
2022/06/15

Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress

Published
2022/06/08

Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022

Published
2022/05/11

Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022

Published
2022/04/28

Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress

Published
2022/04/21

Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022

Published
2022/04/20

Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences

Published
2022/04/01

Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 21 Million

Published
2022/03/31

Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement

Published
2022/03/07

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference

Published
2022/02/28

Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer’s Disease

Published
2022/01/04

Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences

Published
2021/12/22

Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer’s Disease

Published
2021/11/04

Vivoryon Therapeutics N.V. Reports Q3 2021 Financial Results and Highlights Operational Progress

Published
2021/11/01

Vivoryon Therapeutics N.V. to Report Third Quarter 2021 Financial Results on November 4, 2021

Published
2021/10/18

Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer’s Disease

Published
2021/09/21

Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and Operational Progress

Published
2021/09/20

Vivoryon Therapeutics N.V. to Publish its Financial Results for H1 2021 and Operational Progress

Published
2021/06/29

Vivoryon Therapeutics Provides Update on Financial Guidance

Published
2021/06/29

Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer’s Disease in Greater China

Published
2021/06/28

Ordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.

Published
2021/06/25

Vivoryon Therapeutics Announces Financial Results for the First Quarter of 2021 and Provides Corporate Update

Published
2021/05/31

Vivoryon Therapeutics Reschedules Reporting of 1st Quarter 2021 and Provides Update for Annual General Meeting of Shareholders

Published
2021/05/17

Vivoryon Therapeutics Announces Notice of its Annual General Meeting of Shareholders to be Held on June 28, 2021

Published
2021/04/30

Vivoryon Therapeutics N.V. Reports Full Year 2020 Financial Results

Published
2021/04/14

Vivoryon Therapeutics N.V. Reschedules the Reporting of the Full Year 2020 Financial Results to April 30, 2021

Published
2021/04/01

Vivoryon Therapeutics to Host Virtual Event on Current Clinical Landscape in Alzheimer’s Disease Treatment Options with Leaders and Experts on April 15th, 2021

Published
2021/03/12

Extraordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.

Published
2021/01/29

Vivoryon Therapeutics N.V. Announces Nominations to Reappoint Ulrich Dauer as CEO and to Appoint Florian Schmid as CFO

Published
2021/01/06

Vivoryon Therapeutics N.V. new ISIN code

Published
2020/12/16

Vivoryon Therapeutics N.V. new Home Member State

Published
2020/12/14

Successful Relocation of Vivoryon Shares Package

Published
2020/11/30

Vivoryon Therapeutics AG Announces Conversion into Vivoryon Therapeutics N.V.

Published
2020/11/26

Vivoryon Therapeutics Reports Third Quarter 2020

Published
2020/11/19

Vivoryon Therapeutics AG to Publish its Third Quarter 2020 Business Update on November 26, 2020

Published
2020/10/01

Ordinary General Meeting of Shareholders of Vivoryon Therapeutics AG

Published
2020/09/03

Vivoryon Therapeutics Announces Notice of its Ordinary General Meeting of Shareholders to be Held on September 30, 2020

Published
2020/08/27

Vivoryon Therapeutics AG plans conversion into Naamloze Vennootschap (N.V.) under Dutch law

Published
2020/08/27

Vivoryon Therapeutics AG Reports Financial Results for H1 2020 and Provides Corporate Update

Published
2020/08/20

Vivoryon Therapeutics AG to Publish its Half Year 2020 Results on August 27, 2020

Published
2020/08/04

Vivoryon Receives IND Approval for Varoglutamstat‘s (PQ912) Phase 2 Study in Alzheimer’s Disease

Published
2020/07/15

Vivoryon Therapeutics Announces Enrollment of First Patient in VIVIAD, European Phase 2b Alzheimer’s Disease Study with Varoglutamstat (PQ912)

Published
2020/06/26

Vivoryon Therapeutics Provides Update on US and EU Alzheimer’s Clinical Trial Program with PQ912

Published
2020/05/14

Vivoryon Therapeutics AG Reports First Quarter 2020

Published
2020/05/12

Vivoryon Therapeutics AG Postpones Annual General Meeting

Published
2020/05/07

Vivoryon Therapeutics AG to Publish its First Quarter 2020 Business Update on May 14, 2020

Published
2020/04/29

Vivoryon Therapeutics Announces Outcome of Exclusive Option Deal with MorphoSys

Published
2020/04/16

Vivoryon Therapeutics Starts Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer’s Disease

Published
2020/03/26

CORRECTION: Vivoryon Therapeutics AG Reports Full Year 2019 Financial Results

Published
2020/03/26

Vivoryon Therapeutics AG Reports Full Year 2019 Financial Results

Published
2020/03/19

Vivoryon Therapeutics AG to Publish its Full Year 2019 Results on March 26, 2020

Published
2020/03/18

Vivoryon Therapeutics Announces Update on Phase 2b Alzheimer’s Clinical Trial, VIVIAD

Published
2020/03/03

Vivoryon Therapeutics to Attend Upcoming Investor Conferences

Published
2020/01/14

Vivoryon Therapeutics and Nordic Bioscience Enter Research and Development Collaboration

Published
2020/01/07

Vivoryon Therapeutics to Attend 38th Annual J.P. Morgan Healthcare Conference in January 2020

Published
2019/12/20

Vivoryon Therapeutics is Included in AScX Index

Published
2019/11/28

Vivoryon Therapeutics Reports Third Quarter 2019

Published
2019/11/27

Vivoryon Therapeutics attends CTAD 2019

Published
2019/11/21

Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019

Published
2019/11/04

Vivoryon Therapeutics to Attend and Present at Investor Conferences in November 2019

Published
2019/10/24

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS RELEASE.

Published
2019/10/08

Published
2019/08/29

Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update

Published
2019/08/22

Vivoryon Therapeutics AG to Publish its Half Year 2019 Results on August 29, 2019

Published
2019/07/08

MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology

Published
2019/06/27

Vivoryon Therapeutics AG enters myeloid immune checkpoint drug discovery, and collaborates with the University of Kiel to select cancer therapy candidates from its QPCTL inhibitor portfolio

Published
2019/06/18

Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of its innovative QPCTL technology into immuno-oncology

Published
2019/06/12

Probiodrug AG becomes Vivoryon Therapeutics AG

Published
2019/05/29

Ordinary General Meeting of Shareholders of Probiodrug AG

Published
2019/05/22 at 07:04

Probiodrug to attend International Conferences in June 2019

Published
2019/05/16

Probiodrug Reports First Quarter 2019 Business Update

Published
2019/05/09

Probiodrug AG to Publish its First Quarter 2019 Business Update on May 16, 2019

Published
2019/04/18

Probiodrug AG to hold its Ordinary General Meeting of Shareholders on 29 May 2019

Published
2019/04/15

Probiodrug raises EUR 8.2 million in successful private placement of new shares

Published
2019/04/09

Probiodrug raises EUR 8.2 million from investors in successful private placement of new shares

Published
2019/04/04

Probiodrug AG has mandated ODDO SEYDLER BANK AG as Designated Sponsor

Published
2019/03/28

Probiodrug reports full year 2018 financial results

Published
2019/03/21

Probiodrug AG to Publish its Full Year 2018 Results on March 28, 2019

Published
2019/03/20

Probiodrug and Alzheimer’s Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (NIH) Grant for U.S. Phase 2b Core Program for PQ912

Published
2019/03/12

Probiodrug to attend BIO Europe Spring in March 2019

Published
2019/02/05

Probiodrug to attend International Conferences in February 2019

Published
2018/12/18

Probiodrug to attend at J.P. Morgan Healthcare Conference in January 2019